# Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

Source: https://onco.cc/trials/nct04446117/  
OnCo record `nct04446117` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Cabozantinib, Atezolizumab, Abiraterone acetate in prostate cancer, run by Exelixis, active and no longer recruiting.

## Summary

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC is a phase 3 interventional study registered as NCT04446117 by Exelixis, with 575 participants enrolled, started 2020-10-19 and due to reach its primary completion in 2024-04-19. Interventions recorded: Cabozantinib, Atezolizumab, Abiraterone Acetate, Enzalutamide, Prednisone. Conditions listed: Metastatic Prostate Cancer, Prostate Adenocarcinoma. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Also known as: CONTACT-02
- Tags: ctgov-ingest
- Registry id: NCT04446117
- Phase: 3
- Setting: A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer
- Sponsor: Exelixis
- Enrolled: 575
- Outcomes: Duration of Progression Free Survival (PFS) Per Response Evaluable Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Radiology Committee (BIRC): Experimental Arm: Cabozantinib and Atezolizumab 6.34 months vs Control Arm: Second NHT 4.17 months; Duration of Overall Survival (OS): Experimental Arm: Cabozantinib and Atezolizumab 14.78 months vs Control Arm: Second NHT 14.98 months

## Sources

- ClinicalTrials.gov NCT04446117: https://clinicaltrials.gov/study/NCT04446117

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Abiraterone acetate](https://onco.cc/drugs/abiraterone/), [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Cabozantinib](https://onco.cc/drugs/cabozantinib/), [Enzalutamide](https://onco.cc/drugs/enzalutamide/), [Prednisone](https://onco.cc/drugs/prednisone/)
- companies: [Exelixis](https://onco.cc/companies/exelixis/)
- key papers: [Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial](https://onco.cc/key-papers/paper-nct04446117-lancet-oncol-2025/)

---
JSON: https://onco.cc/api/v1/entities/nct04446117.json